Literature DB >> 19402929

Cognitive decline in Parkinson's disease: a prospective longitudinal study.

Dino Muslimović1, Bart Post, Johannes D Speelman, Rob J De Haan, Ben Schmand.   

Abstract

This controlled prospective study examined the evolution and predictors of cognitive decline in Parkinson's disease (PD). Consecutive patients diagnosed at baseline with PD (n = 89), established PD (EPD) patients (n = 52) with a mean disease duration of 6.5 years, and healthy control subjects (n = 64) underwent extensive neuropsychological assessment twice, approximately 3 years apart. A standardized regression-based method, normative data, and multivariate normative comparisons were used to assess the cognitive course of PD. Cognitive performance of newly diagnosed patients decreased significantly over time, particularly on measures of psychomotor speed and attention and to a lesser extent on tests of memory, visuospatial skills, and executive functions. About 50% of the patients showed cognitive decline and 9% developed dementia. Similar results were observed in EPD patients. None of the baseline features predicted cognitive change in newly diagnosed patients, whereas age at disease onset and axial impairment (postural and gait disorders) contributed to decline in established patients. We conclude that within few years after diagnosis, PD patients show faster rate of cognitive decline than matched healthy subjects, particularly in domains of attention and psychomotor speed. Selection bias probably led to underestimation of the true extent of cognitive decline in established patients.

Entities:  

Mesh:

Year:  2009        PMID: 19402929     DOI: 10.1017/S1355617709090614

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  49 in total

Review 1.  Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods.

Authors:  Kevin Duff
Journal:  Arch Clin Neuropsychol       Date:  2012-02-29       Impact factor: 2.813

Review 2.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

3.  Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Authors:  Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  J Int Neuropsychol Soc       Date:  2010-11-24       Impact factor: 2.892

Review 4.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

5.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Anat Mirelman; Rachel Saunders-Pullman; Deborah Raymond; Christina Palmese; Elise Caccappolo; Laurie Ozelius; Avi Orr-Urtreger; Lorraine Clark; Nir Giladi; Susan Bressman; Karen Marder
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

6.  Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Authors:  Jenny Ceccarini; Cindy Casteels; Rawaha Ahmad; Melissa Crabbé; Laura Van de Vliet; Heleen Vanhaute; Mathieu Vandenbulcke; Wim Vandenberghe; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

7.  Cognitive reserve and β-amyloid pathology in Parkinson disease.

Authors:  Carolyn Lucero; Meghan C Campbell; Hubert Flores; Baijayanta Maiti; Joel S Perlmutter; Erin R Foster
Journal:  Parkinsonism Relat Disord       Date:  2015-05-27       Impact factor: 4.891

8.  Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

Authors:  R N Alcalay; E Caccappolo; H Mejia-Santana; M -X Tang; L Rosado; M Orbe Reilly; D Ruiz; B Ross; M Verbitsky; S Kisselev; E Louis; C Comella; A Colcher; D Jennings; M Nance; S Bressman; W K Scott; C Tanner; S Mickel; H Andrews; C Waters; S Fahn; L Cote; S Frucht; B Ford; M Rezak; K Novak; J H Friedman; R Pfeiffer; L Marsh; B Hiner; A Siderowf; H Payami; E Molho; S Factor; R Ottman; L N Clark; K Marder
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

9.  Aging in fragile X syndrome.

Authors:  Agustini Utari; Evan Adams; Elizabeth Berry-Kravis; Alyssa Chavez; Felicia Scaggs; Lily Ngotran; Antoniya Boyd; David Hessl; Louise W Gane; Flora Tassone; Nicole Tartaglia; Maureen A Leehey; Randi J Hagerman
Journal:  J Neurodev Disord       Date:  2010-05-12       Impact factor: 4.025

10.  Impaired verbal memory in Parkinson disease: relationship to prefrontal dysfunction and somatosensory discrimination.

Authors:  Stephan Bohlhalter; Eugenio Abela; Dorothea Weniger; Bruno Weder
Journal:  Behav Brain Funct       Date:  2009-12-15       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.